oncoExTra™

by EXACT SCIENCES

Covered by MEDICARE

A Comprehensive and Easy to Interpret Clinical Report

The OncoExTra™ assay is an **ultra-comprehensive genomic profiling test** that incorporates whole-exome and whole-transcriptome* sequencing to identify alterations/ biomarkers in patients diagnosed with all types of advanced cancers. These insights can help inform targeted therapy or immunotherapy selection, and clinical trials eligibility.

The OncoExTra Test Provides:

- 3 report types: OncoExTra + IHC†, OncoExTra Only, or IHC Only
- Easy to interpret "Results Snapshot" on page 1 of the report
- Color coded sections to help correlate findings

Drugs predicted to have no or reduced benefit as supported by literature

Additional therapeutic options outside of patient's cancer sub-type

Targetable Mutations and Associated Therapies

TMB & MSI Status

High Interest Biomarkers



oncoExTra™

EXACT SCIENCES

Report Date: MM/DD/YYYY

Patient:	Sample Patient	Ordering Client:	Medical Center
Sex at Birth:	Female	Specimen Type:	FFPE Block
DOB:	MM/DD/YYYY	Specimen Site:	Lung
Medical Record #:	MR 00000	Tumor Collection Date:	MM/DD/YYYY
Client Accession #:	CA 000000	Normal Collection Date:	MM/DD/YYYY
Ordering Physician:	Sample Physician	Received Date:	MM/DD/YYYY

Results Snapshot
Analytes sequenced: DNA+RNA+IHC
Actionable Targets: 5 IHC Tested: 1
TMB: Intermediate PD-L1: See Below
MSI: Stable
Clinical Trials: Yes

Diagnosis: **Lung Cancer**

KEY BIOMARKER FINDINGS

KEY BIOMARKERS	FDA-APPROVED DRUGS -for patient's cancer[1]	FDA-APPROVED DRUGS -for another cancer[1]	DRUGS PREDICTED NON-BENEFICIAL/ REDUCED BENEFIT	POTENTIAL CLINICAL TRIALS
TUMOR GENOMIC ALTERATIONS				
ARID1A (S2249*)				Yes
CD74/ROS1	crizotinib, entrectinib	cabozantinib, ceritinib, lorlatinib		Yes
NF1 (Q369*)		binimetinib, everolimus, temsirolimus, trametinib		Yes
TP53 (I195T)				Yes
TUMOR MUTATION BURDEN (TMB)				
INTERMEDIATE (8 mut/Mb)				No
MICROSATELLITE STATUS (MSI)				
STABLE				No
IHC RESULTS				
PD-L1 (22C3): Low	atezolizumab, durvalumab, nivolumab, nivolumab + ipilimumab, pembrolizumab	dostarlimab-gxly		

HIGH INTEREST BIOMARKERS

*As part of the OncoExTra test, key biomarkers relevant in the patient's tumor type have been assessed: **NTRK1, NTRK2, NTRK3, RET, BRAF, ALK, EGFR, ERBB2, KRAS, MET, ROS1, PD-L1**. If clinically pertinent event(s) in these biomarkers have been identified, the biomarker(s) will appear within the 'Key Biomarker Findings' section of the report. If Biomarkers from this list do not appear, clinically pertinent event(s) have not been identified or fell outside of the OncoExTra reporting thresholds (please see Disclaimer Limitations information).*

[1]The prescribing information for the FDA-approved therapeutic option may not include the associated Key Biomarker.

Janine LoBello, DO, Laboratory Director
Genomic Health, Inc. 445 N 5th Street Phoenix, AZ 85004 tel:1-866-662-6897

Page 1 of 19

Snapshot of Key findings

Clinical Trial Options

IHC Results with therapeutic indications

*Whole-transcriptome with select variants reported in New York State
†IHC testing is not currently available in New York State

Additional Report Details

Additional Significant Alterations

ADDITIONAL SIGNIFICANT ALTERATIONS	
MAP2K4 (R228I)	No

Genomic Alteration Detail

Genomic Alteration		Therapeutic Implication	
Alteration:	ARID1A (S2249*)	**Drug**	**Status**
Alteration Type:	Stop Gain	See Clinical Trials Section	
Coordinate:	chr1:27107135		
Allele Frequency:	24%		
Origin:	DNA		
Read Depth:	465		
Location:	20/20		

Drug Evidence Detail

Literature Supporting Therapeutic Implication

Drug	Biomarker	Therapeutic Implication
ceritinib (Zykadia)	CD74/ROS1 (Fusion)	PREDICTED BENEFICIAL

ROS1 rearranged NSCLC patients (n=32) were enrolled in a phase II ceritinib trial. The ORR was 63% with 1 complete response and 19 partial responses. The median duration of response was 10.0 months. The median PFS was 19.3 months and the median OS was not reached at the time of the data cut off.

Clinical Trials

Potential trials based on genomic targets indicated in the OncoExTra Report

Genomic Alterations	Targeted Investigational Agents	Trial IDs
ARID1A (S2249*)	AKT inhibitors: (Afuresertib [GSK2110183], Capivasertib [AZD-5363], Ipatasertib [GDC-0068, RG-7440], Miransertib [ARQ092], ARQ751, MK-2206, Triciribine [TCN-P]), ATR inhibitors: (Berzosertib [M	NCT05023655 NCT02264678 NCT02484404 NCT05053971 NCT01582191 NCT03065062

IHC Score Detail

1 IHC Tested

IHC BIOMARKER	IHC Data	Status	Approved By
PD-L1 (22C3)	%TPS: 5-9	Low	Dr. Sample Pathologist (MM/DD/YEAR)

To Learn More: OncoExTra.com | To Order: OncoExTra.com/order

EXACT SCIENCES

OncoExTra has been validated according to the guidelines set forth by the New York State Department of Health. Whole exome (DNA) events have been validated to include point mutations, indels, and copy number alterations, as well as MSI analysis and TMB calculation. Whole transcriptome (RNA) has been validated to report on select fusion genes and special transcripts.